Drug Name:
MULTIHANCE Rx
Generic Name and Formulations:
Gadobenate dimeglumine 529mg/mL; soln for IV inj; preservative-free.
Company:
Bracco Diagnostics
Therapeutic Use:
Indications for MULTIHANCE:
For use in MRI of the CNS in adults and children to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine, and associated tissues. For use in magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.
Adults and Children:
MRI: Preterm neonates: not established. Give as a rapid IV bolus inj, followed by a saline flush of ≥5mL to ensure complete injection. <2yrs: 0.1–0.2mL/kg. ≥2yrs: 0.2mL/kg (0.1mmol/kg). MRA: <18yrs: not established. ≥18yrs: 0.2mL/kg (0.1mmol/kg) by rapid IV bolus inj, followed by a saline flush of ≥20mL either manually or using an automatic injector system.
Boxed Warning:
Nephrogenic systemic fibrosis.
Warnings/Precautions:
Increased risk of nephrogenic systemic fibrosis in chronic kidney disease or acute kidney injury; avoid use. Screen for renal dysfunction. Do not exceed recommended dose and allow sufficient time for drug elimination before re-administration. Have emergency resuscitative equipment available. History of asthma or other allergic disorders. Monitor for signs/symptoms of hypersensitivity reactions during and for 2hrs after administration. Increased risk of gadolinium retention with multiple lifetime doses, in pregnant patients, children, and those with inflammatory conditions; minimize repetitive imaging studies. Underlying conditions or medications that predispose to cardiac arrhythmias. Dubin Johnson syndrome. Avoid extravasation. Interpreting contrast MR images in the absence of companion non-contrast MR images. Elderly. Pregnancy. Nursing mothers.
Pharmacological Class:
Gadolinium-based contrast agent.
Interactions:
May potentiate concomitant drugs that compete for cMOAT sites (eg, cisplatin, anthracyclines, vinca alkaloids, methotrexate, etoposide, tamoxifen, paclitaxel).
Adverse Reactions:
Nausea, headache, inj site reaction, feeling hot; hypersensitivity.
How Supplied:
Single dose vials (5mL, 10mL, 15mL, 20mL)—5
Clinical Pain Advisor Articles
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- The Challenge of Compassion in Modern Healthcare Settings
- Republican Opposition to Obamacare: What's Done, What's to Come
- Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription Numbers
- Steps Taken to Increase Use of Electronic Tools in Medicine
- Daily and Retrospective Pain Measurements Comparable in Hip Osteoarthritis
